• 1.

    Schrier RW, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:20992112. doi: 10.1056/NEJMoa065181

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Berl T, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705712. doi: 10.1681/ASN.2009080857. Erratum in: J Am Soc Nephrol 2010; 21:1407. https://jasn.asnjournals.org/content/21/8/1407.2

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:24072418. doi: 10.1056/NEJMoa1205511

  • 4.

    Torres VE, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377:19301942. doi: 10.1056/NEJMoa1710030

  • 5.

    Edwards ME, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2018; 13:11531161. doi: 10.2215/CJN.01520218

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Malhotra I, et al. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: Case review on role of vaptans. Case Rep Endocrinol 2014; 2014:807054. doi: 10.1155/2014/807054

    • Search Google Scholar
    • Export Citation
  • 7.

    Sterns RH. Tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone: Is the dose too high? Am J Kidney Dis 2018; 71:763765. doi: 10.1053/j.ajkd.2018.02.355

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Erickson KF, et al. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013; 159:382389. doi: 10.7326/L14-5001-7

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Jamookeeah C, et al. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord 2016; 16:22. doi: 10.1186/s12902-016-0104-z

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Chebib FT, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018; 29:24582470. doi: 10.1681/ASN.2018060590

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Gross P, et al. Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers? Nephrol Dial Transplant 2019; 34:3537. doi: 10.1093/ndt/gfy298

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Meijer E, Gansevoort RT. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: Efficacy, safety, and tolerability. Kidney Int 2020; 98:289293. doi: 10.1016/j.kint.2020.03.023

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Gordon CE, Perrone RD. Tolvaptan or transplant: Why wait? Kidney Int 2020; 98:286289. doi:10.1016/j.kint.2020.03.022.Erratum in: Kidney Int 2020; 98:1622. doi: 10.1016/j.kint.2020.11.002

    • Crossref
    • Search Google Scholar
    • Export Citation

Light and Shadow in Oral Tolvaptan Treatment

  • 1 Yong Chul Kim is an associate professor and Hajeong Lee is a professor in the Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Restricted access
Save